ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,212.20
0.10%
S&P ASX All Technology
3,444.90
0.35%
Brent Oil
70.925
-0.04%
US Dollar vs AUD
1.44976
-0.08%
Bitcoin
65,461.36
0.43%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Recursion Pharmaceuticals Inc (RXRX)

  7. Recursion Pharmaceuticals Inc (RXRX) News

RXRX

Recursion Pharmaceuticals (RXRX)

Recursion Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:RXRX
DateTimeSourceHeadlineSymbolCompany
27/09/202406:14Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
20/09/202407:48Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
20/09/202406:27Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:RXRXRecursion Pharmaceuticals Inc
18/09/202406:13Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
17/09/202420:03Edgar (US Regulatory)Form PREM14A - Preliminary proxy statements relating to merger or acquisitionNASDAQ:RXRXRecursion Pharmaceuticals Inc
13/09/202408:28Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
12/09/202407:15Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
11/09/202407:00Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
07/09/202406:57Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
06/09/202407:25Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
06/09/202401:43Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
05/09/202407:24Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:RXRXRecursion Pharmaceuticals Inc
05/09/202403:16Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
04/09/202406:48Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
04/09/202406:27Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
03/09/202422:02Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:RXRXRecursion Pharmaceuticals Inc
03/09/202422:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RXRXRecursion Pharmaceuticals Inc
03/09/202422:00GlobeNewswire Inc.Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and TolerabilityNASDAQ:RXRXRecursion Pharmaceuticals Inc
31/08/202406:26Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
30/08/202406:53Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
30/08/202406:22Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
29/08/202406:49Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:RXRXRecursion Pharmaceuticals Inc
29/08/202406:45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RXRXRecursion Pharmaceuticals Inc
29/08/202406:12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
28/08/202406:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
27/08/202406:42Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
24/08/202407:25Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
23/08/202408:48Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
21/08/202406:25Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
20/08/202409:09Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:RXRX

Your Recent History

COIN
PAYTOMATBTC
COIN
LCSSBTC
BOV
BILB34
Banco Bilbao Vizcaya Arg...
COIN
LRAEUR
TSX
RBOT.U
Global X Robotics and AI
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved